The Invention A new application / Use for Calcitriol - It was demonstrated, in vitro, that calcitriol and some of its synthetic analogs have the potential to reduce the damage inflicted to normal tissue by accepted anti-cancer therapy. Vitamin D offers protection from programmed cell death to ...

Background: The tumor: Malignant primary brain tumors and especially the highly malignant Glioblastoma Multiforme (GBM) are fatal within months of diagnosis in almost all patients. There are more than 20,000 patients in the US and approximately 200,000 patients worldwide that are diagnosed ...

The Invention TA is a broad spectrum antibiotic differing from known antibiotics by virtue of its adhesiveness to synthetic materials and to biological tissues, whilst retaining its bactericidal activity in the bou nd form. TA may be topically administered to the implanted device or infected zone ...

Background Glaucoma is a disease characterized by intra-ocular pressure sufficient to damage the optic nerve and cause permanent impairment of vision. Glaucoma is rarely cured, but its progression can be greatly delayed by reducing the intra-ocular pressure with medicines, laser procedure or ...

Patches derived from tree gum exudate for transdermal and topical drug delivery Category Topical and transdermal drug delivery system Development Stage In vivo and in vitro results Patent Status U.S. patent filed Market Size Annual U.S. market for transdermal patches ...

The Invention A series of novel soluble adamantyl-oligoethyleneglycol-fullerene hybrids was prepared via Bingel-Hirsch functionalization of C60 fullerene with various adamantyl-oligoethyleneglycol malonates. As NMDA-targeted antioxidants, these compounds have potential as therapeutic agents for the ...

Additional material on the technology can be supplied upon ...

Additional material on the technology can be supplied upon ...

Novel treatment for diseases associated with pathogenic microorganisms Categories Antimicrobial, antifungal, antiparasitic, antimalarial Development Stage Interactive website established Patent Status U.S. patent application filed (PCT publication No. WO2007032004) Market ...

The present invention relates to an antibody fragment capable of binding to P-glycoprotein associated with multidrug resistant (MDR) cells. The present invention also relates to compositions and methods utilizing such an antibody fragment for inhibiting drug efflux activity in MDR cancer cells. ...

A number of gene therapies have entered late stage clinical trials since year 2000. Innovative gene therapy technology may have several potential benefits over the conventional drugs, such as activity in the target region only, causing lower side effects and a better efficacy in the target tissue. ...

An unprecedented strategy is proposed for the prophylactic treatment of asthma as well as other inflammatory associated diseases, such as rheumatoid arthritis. This novel pharmaceutical platform is based on a recent discovery that inflammation involves generation of ozone by white blood cells, and ...

Antibodies from mouse lymphoma cells recognize human breast cancer Categories Oncology, breast cancer diagnosis and treatment, antibodies Development Stage Positive results obtained in mice and in small number of human samples Patent Status U.S. patent pending, PCT publication ...

The Invention ASSNAC, S-allymercapto-N-acetylcysteine, is a small bi-functional molecule that up-regulates cellular glutathione levels, the major cellular anti-oxidant. ASSNAC dissociates in peripheral tissues, slowly releasing s-allylmercaptan and NAC. s-allylmercaptan, the thiol-active component ...

Neomycin B is an important antibiotic, commonly used as food-additive for agricultural purposes. As a result of antibiotic formulation having been used for several decades, resistance to antibiotics has been evolving. The present invention is of a modified Neomycin B by addition of one extra sugar ...

Background MM is a severe and incurable plasma cell malignancy and the second most common blood cancer. The median survival of untreated patients is approximately 10 months. Aggressive chemotherapy may prolong life to an average of 15-40 months. No cure has been found for MM. There is an unmet ...

Description of Technology Bleeding is normally stopped by hemostasis through several sequential processes that produce blood clotting – the body’s major defence against blood loss. The last step in the blood clotting process consists of the formation of insoluble fibrin matrix due to the ...

Current interest in vaccination technology revolves around the prospect of “biopharming,” or the expanding technologies stemming from agricultural biotechnology. Initial products have focused mainly on strengthening crops by developing their own biopesticides as well as enhancing ...

Anti-inflammatory action of 2-arachidonylglycerol (2-AG) protects brain Categories Brain injury, neuro-protection, anti-inflammatory Development Stage Clinical studies in mice completed and results published Patent Status A US patent, 5,605,928, has been approved. Market ...